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Clinical PerspectiveWhat Is New?This study examined the smoking paradox in relation to confounding by severity of illness related variables in a Middle Eastern population admitted for heart failure.The relationship between smoking behavior at admission and mortality is reexamined from a methodological perspective comparing traditional covariate adjustment with covariate balancing via propensity score--based weights.What Are the Clinical Implications?The smoking paradox is probably not a causal effect but rather a bias that has been incompletely addressed analytically.There are many confounding variables related to severity of illness in registry‐based observational cardiovascular studies, making residual confounding a serious problem when assessing causal effects, on outcome, of specific factors (such as smoking).The results in this article suggest that covariate balancing using propensity score--based weights can help avoid such paradoxical results when compared with traditional covariate adjustment in the assessment of causal effects.

 {#jah34420-sec-0009}

Smoking is a strong risk factor for premature atherosclerosis, myocardial infarction (MI), heart failure (HF), and sudden cardiac death. It is estimated that smokers lose at least one decade of life expectancy, compared with those who have never smoked.[1](#jah34420-bib-0001){ref-type="ref"} Yet, despite the well‐established and modifiable risk associated with smoking, several studies have demonstrated that the short‐term mortality after acute coronary syndromes (ACSs) or associated HF[2](#jah34420-bib-0002){ref-type="ref"} is lower in current smokers (CSs) compared with current nonsmokers (CNs), the so‐called smoker\'s paradox.[3](#jah34420-bib-0003){ref-type="ref"} This apparent paradox, whereby CS subjects appear to have more favorable outcomes compared with CN subjects, has also been reported in other disease states, including stroke,[4](#jah34420-bib-0004){ref-type="ref"} trauma,[5](#jah34420-bib-0005){ref-type="ref"} cardiac arrest,[6](#jah34420-bib-0006){ref-type="ref"} and preeclampsia.[7](#jah34420-bib-0007){ref-type="ref"}

Smoking perhaps is not the variable that improves the outcome; it is more likely confounded by the different baseline variables that worsen outcome and are likely to induce smoking cessation, most important factors related to severity of illness.[8](#jah34420-bib-0008){ref-type="ref"} The conventional approach used in research has been to adjust for such baseline characteristics when looking for a causal association from observational data.[9](#jah34420-bib-0009){ref-type="ref"} In the latter, an attempt is then made to incorporate key important covariates into a regression model examining the relationship between the exposure and the outcome. Studies using this approach seem to confirm the presence of such a smoking paradox, the paradox being that CS seems to be a "cause" of the improved prognosis.[10](#jah34420-bib-0010){ref-type="ref"}

Unfortunately, such regression models may be overfitted when the numbers with the outcome are small compared with the number of participants and confounders. In addition, the adequacy of model specification needs to be checked and the relationship between the third variables and the outcome needs to meet model specifications (eg, linear within a linear model). All these are potential problems; and despite the fact that standard guidelines suggest having no less than 10 events for each covariate incorporated into the model,[11](#jah34420-bib-0011){ref-type="ref"} it may not be possible to adhere to this when important confounders are many, as is the case in observational research in ACS and HF. An alternative strategy that has emerged is the propensity score (PS), which is progressively being used in observational studies of cardiovascular interventions.[12](#jah34420-bib-0012){ref-type="ref"}, [13](#jah34420-bib-0013){ref-type="ref"}, [14](#jah34420-bib-0014){ref-type="ref"} A PS is characterized as the likelihood of a patient being allocated to an intervention, given a set of exposures.[15](#jah34420-bib-0015){ref-type="ref"} As the PS reduces many patient covariates into a single covariate, it decreases the probability of overfitting.[16](#jah34420-bib-0016){ref-type="ref"} The goal of the PS technique is to attain covariate balance, as is the case with randomized comparisons.

In this study, we decided to compare the covariate adjustment and PS approach to examine, in detail, the effect of smoking status on the in‐hospital mortality of patients hospitalized with acute HF using data from a multicenter multinational HF registry: the Gulf CARE (Gulf Acute Heart Failure Registry).

Methods {#jah34420-sec-0010}
=======

Data will be available from the corresponding author on reasonable request.

Registry Design {#jah34420-sec-0011}
---------------

Details of the Gulf CARE design were previously published.[17](#jah34420-bib-0017){ref-type="ref"}, [18](#jah34420-bib-0018){ref-type="ref"} In summary, Gulf CARE was a multicenter, multinational, prospective, observational study that recruited patients who were admitted with the final diagnosis of acute HF from 47 hospitals in 7 Middle Eastern countries in the Arabian Gulf (Oman, Saudi Arabia, United Arab Emirates, Qatar, Bahrain, Yemen, and Kuwait) during February 2012 to November 2012.[17](#jah34420-bib-0017){ref-type="ref"} Data were collected on episodes of hospitalization, as per a standardized case report form beginning with point of initial care, and including patient\'s discharge, transfer out of hospital, or in‐hospital death, and for those discharged alive at 3 and at 12 months of follow‐up. Study ethical approval was obtained from all concerned authorities in the recruiting centers. Informed consent was obtained from all patients. Each patient was given a unique identification number to prevent double counting.

Study included patients with acute HF from both sexes who were ≥18 years of age and admitted to the participating hospitals. Acute HF was defined on the basis of the European Society of Cardiology definition.[19](#jah34420-bib-0019){ref-type="ref"} Acute HF was further classified as either acute decompensated chronic HF or new‐onset acute HF (de novo) based on European Society of Cardiology guidelines.[19](#jah34420-bib-0019){ref-type="ref"} Acute decompensated chronic HF was defined as worsening of HF in patients with a previous diagnosis or hospitalization for HF. New‐onset acute HF (de novo) was defined as acute HF in patients with no history of HF.

Patients were excluded from the study if the following occurred: (1) they were discharged from the emergency department without admission, (2) they were transferred from a nonregistry hospital, (3) they could not provide informed consent, and (4) their final diagnosis was not HF. Registry organization and data collection and validation have already been outlined in a prior published article of Gulf CARE.[17](#jah34420-bib-0017){ref-type="ref"}, [18](#jah34420-bib-0018){ref-type="ref"}

Definitions of variables in the case report form were based on the European Society of Cardiology guidelines 2008 and the American College of Cardiology clinical data standards 2005.[19](#jah34420-bib-0019){ref-type="ref"}, [20](#jah34420-bib-0020){ref-type="ref"} Diabetes mellitus (DM) was defined as having a history of DM diagnosed and treated with medication and/or insulin or fasting blood glucose of 7.0 mmol/L (126 mg/dL) or glycated hemoglobin ≥6.5%. Hypertension was defined as having a history of hypertension diagnosed and treated with medication, blood pressure \>140 mm Hg systolic or \>90 mm Hg diastolic on at least 2 occasions, or blood pressure \>130 mm Hg systolic or \>80 mm Hg diastolic on at least 2 occasions, for patients with DM or chronic kidney disease (CKD). Hyperlipidemia was defined as history of dyslipidemia diagnosed and/or treated by a physician or total cholesterol \>5.18 mmol/L (200 mg/dL), low‐density lipoprotein cholesterol ≥3.37 mmol/L (130 mg/dL), or high‐density lipoprotein cholesterol \<1.04 mmol/L (40 mg/dL). CS was defined as smoking cigarettes, water pipe, cigar, or chewing tobacco within 1 month of index admission. CKD was defined as glomerular filtration rate \<60 mL/min per 1.73 m^2^ for ≥3 months, with or without kidney damage or on dialysis. If no glomerular filtration rate was available, serum creatinine \>177 mmol/L or 2 mg/dL was marked as CKD. Obesity was defined as body mass index \>25 kg/m^2^. Cardiomyopathy was defined as a myocardial disorder in which the heart muscle is structurally and functionally abnormal (in the absence of coronary artery disease \[CAD\], hypertension, valvular disease, or congenital heart disease), sufficient to cause the observed myocardial abnormality. Infection definition in the registry was any systemic infection needing antibiotics. The presence of CAD was defined as history of CAD, MI, or coronary revascularization procedure, including percutaneous coronary intervention and coronary artery bypass grafting surgery.

Statistical Analysis {#jah34420-sec-0012}
--------------------

Baseline and outcome data were presented as frequency and percentages for categorical variables; and for interval variables, they were presented as means and SDs (and median and interquartile range for nonnormally distributed variables), as appropriate. χ^2^ Tests (or Fisher exact tests for cells \<5) were applied to see if there were associations between CSs and CNs for categorical variables, whereas Student *t* tests were used for normally distributed interval variables and Wilcoxon rank sum tests were used for nonnormally distributed interval variables. The association between smoking and mortality (in hospital) was examined using multivariable logistic regression, adjusting for risk factors potentially related to mortality. These included 3 from *demographics*: age, sex, and country of origin in the Gulf Cooperation Council countries; 9 from *previous history*: prior DM, prior CKD/dialysis, prior hyperlipidemia, prior CAD, prior asthma/chronic obstructive pulmonary disease, prior ACS, prior admission for HF, prior syncope in past 1 year, and prior use of aspirin; 3 from a*dmission status*: body mass index on admission, New York Heart Association class at admission, and admitted to intensive care unit; and, finally, 2 from *course in hospital:* intubation/ventilation and atrial fibrillation requiring therapy. Adjusted odds ratios (ORs) and 95% CIs were used to quantify the association between baseline variables and mortality.

In the second analysis, the PS for an individual was defined as the probability of being in the exposure group given all relevant covariates. The PS was estimated using a logistic regression model that incorporated all variables listed above used for the covariate adjustment model. After the PS was calculated, weights were applied to the regression model corresponding to 1/PS for patients in the CS cohort and \[1/(1−PS)\] for those in the CN cohort. No trimming was performed of these weights in the main analysis, but a sensitivity analysis restricting data to a subsample with PS between 0.01 and 0.99 as well as between 0.1 and 0.9 was performed as a sensitivity analysis. The weighted data were checked for covariate balance using standardized differences between CS and CN subjects before and after weighting. On the graph of standardized differences, horizontal lines denoting standardized differences of ±0.1 are indicated as it has been suggested that standardized differences that exceed these thresholds may be indicative of meaningful imbalance.[21](#jah34420-bib-0021){ref-type="ref"} For comparison, we provide the crude effect estimate, the covariate‐adjusted effect estimate, and the PS model weighted estimate. *P*\<0.05 (2 tailed) was considered statistically significant. Stata, version 15 (StataCorp, College Station, TX), was used for the analysis.

Results {#jah34420-sec-0013}
=======

Baseline Characteristics {#jah34420-sec-0014}
------------------------

The study included 5005 patients hospitalized with acute HF, of whom 1103 (22%) were CSs. CS subjects were 6 years younger and more likely to present with acute decompensated chronic HF. Compared with nonsmokers, smokers were less likely to present with a history of CAD, left ventricular dysfunction, valvular heart disease, stroke/transient ischemic attacks, DM, hypertension, hyperlipidemia, CKD, asthma/chronic obstructive pulmonary disease, and thyroid disease, whereas CN subjects were more likely to have family history of cardiomyopathy/HF. CS subjects were less likely to be taking aspirin, digoxin, oral nitrates, and other evidence‐based medications before admission (Table [1](#jah34420-tbl-0001){ref-type="table"}).

###### 

Baseline Characteristics of Subjects in the Registry

  Characteristics                                  Smokers (n=1103; 22%)   Nonsmokers (n=3902; 78%)   *P* Value
  ------------------------------------------------ ----------------------- -------------------------- -----------
  HF type                                                                                             
  Acute new‐onset HF                               428 (39)                2289 (59)                  0.001
  Acute decompensated chronic HF                   675 (61)                1613 (41)                  
  Age, mean±SD, y                                  55±12                   61±15                      0.001
  Women                                            83 (7.5)                1791 (46)                  0.001
  Ethnicity/race                                                                                      
  Arab                                             945 (85.7)              3571 (91.5)                
  Asian                                            154 (14)                319 (8.2)                  
  Other                                            4 (0.4)                 12 (0.3)                   
  Previous cardiovascular history                                                                     
  Known systolic LV dysfunction                    351 (32)                1930 (50)                  0.001
  Known CAD                                        432 (39)                1905 (49)                  0.001
  Valvular heart disease                           63 (6)                  612 (16)                   0.001
  Congenital heart disease                         7 (0.6)                 34 (0.9)                   0.44
  PVD                                              46 (4)                  177 (4.5)                  0.60
  Stroke/TIA                                       65 (6)                  339 (8.7)                  0.003
  Family history of cardiomyopathy/heart failure   96 (8.7)                163 (4)                    0.001
  Other comorbidities                                                                                 
  Diabetes mellitus                                439 (40)                2053 (53)                  0.001
  Hypertension                                     540 (49)                2519 (65)                  0.001
  Hyperlipidemia                                   345 (31)                1454 (37)                  0.001
  CKD/dialysis                                     69 (6)                  675 (17)                   0.001
  Sleep apnea requiring therapy                    11 (1)                  88 (2.3)                   0.008
  Asthma/COPD                                      88 (8)                  413 (10.6)                 0.01
  Thyroid disease                                  8 (0.7)                 173 (4.4)                  0.001
  Clinical and biochemical parameters                                                                 
  HR, mean±SD, bpm                                 100±20                  96±23                      0.001
  Systolic blood pressure, mean±SD, mm Hg          137±33                  137±34                     0.95
  Diastolic blood pressure, mean±SD, mm Hg         85±19                   80±20                      0.001
  RR, median (IQR), /min                           25 (22--29)             24 (20--28)                0.001
  BMI, mean±SD, kg/m^2^                            27±5                    28±6.6                     0.001
  Pulse oximetry saturation, mean±SD, %            92±6                    93±7                       0.88
  NT‐proBNP, median (IQR), pg/mL                   3324 (1445--6246)       3190 (1313--7428)          0.06
  Elevated troponin                                458 (42)                1444 (37)                  0.006
  HbA1c, mean±SD, %                                7.0±2.4                 7.3±2.0                    0.07
  Total cholesterol, mean±SD, mmol/L               5.5±2.7                 4.6±2.1                    0.001
  Creatinine, mean±SD, μmol/L                      123±112                 132±117                    0.03
  ECG rhythm AF/flutter                            79 (7)                  600 (15)                   0.001
  LVEF, mean±SD, %                                 35±12.5                 37±14                      0.001
  Cause                                                                                               
  Noncompliance with medications                   209 (19)                755 (19)                   0.77
  Noncompliance with diet                          18 (1.6)                118 (3)                    0.01
  Acute coronary syndromes                         428 (39)                937 (24)                   0.001
  Uncontrolled hypertension                        77 (7)                  333 (8.5)                  0.10
  Uncontrolled arrhythmia                          42 (4)                  259 (6.6)                  0.001
  Anemia                                           24 (2)                  130 (3)                    0.05
  Infection                                        130 (12)                601 (15)                   0.003

Data are given as number (percentage), unless otherwise indicated. Analyses were performed using Student *t* test, Wilcoxon‐Mann‐Whitney test, or Pearson\'s χ^2^ test, wherever appropriate. AF indicates atrial fibrillation; BMI, body mass index; bpm, beats per minute; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HbA1c, glycated hemoglobin; HF, heart failure; HR, heart rate; IQR, interquartile range; LV, left ventricular; LVEF, LV ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; PVD, peripheral vascular disease; RR, respiratory rate; TIA, transient ischemic attack.
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Precipitating Factors for HF Hospitalization {#jah34420-sec-0015}
--------------------------------------------

ACS was significantly more common in CSs, whereas noncompliance with diet, uncontrolled arrhythmias, and systemic infections were more common in CNs as possible precipitating factors for hospitalization. (Table [1](#jah34420-tbl-0001){ref-type="table"})

Clinical and Biochemical Parameters {#jah34420-sec-0016}
-----------------------------------

On presentation, CSs had significantly lower rates of atrial arrhythmia and a lower mean ejection fraction. CSs had higher rates of serum troponin and a lower creatinine compared with CNs (Table [1](#jah34420-tbl-0001){ref-type="table"}).

In‐Hospital Course {#jah34420-sec-0017}
------------------

CSs were more likely to be treated with inotropes, whereas the rates of noninvasive ventilations and acute dialysis or blood transfusion for major bleeding were more commonly used in CNs. Also, CNs were more likely to have systemic infections requiring antibiotics. The rates of invasive ventilation, intra‐aortic balloon pump insertion, and the risk of development of stroke were comparable between the 2 groups. At discharge, CSs were more likely to be prescribed digoxin, aspirin, clopidogrel, β blockers, angiotensin‐converting enzyme inhibitors, and aldosterone antagonists, whereas CNs were more likely to be discharged on hydralazine and oral anticoagulants. Cardiac procedures, including interventions and device therapy, were low in the 2 groups, with percutaneous coronary interventions performed more often in CSs. The CS subjects had higher rates of ventricular tachycardia/fibrillation requiring therapy, whereas CNs had higher rates of atrial fibrillation requiring therapy. The crude in‐hospital mortality rate was lower in CSs than CNs (4.8% versus 6.7%; *P*=0.02) (Table [2](#jah34420-tbl-0002){ref-type="table"}).

###### 

In‐Hospital Course of Registry Subjects

  Variables                                  Smokers (n=1103; 22%)   Nonsmokers (n=3902; 78%)   *P* Value
  ------------------------------------------ ----------------------- -------------------------- -----------
  In‐hospital course                                                                            
  NIV                                        79 (7.2)                394 (10)                   0.003
  Intubation/ventilation                     97 (8.8)                327 (8.4)                  0.66
  Inotropes                                  231 (21)                552 (14)                   0.001
  IABP insertion                             21 (2)                  61 (1.6)                   0.43
  Acute dialysis/ultrafiltration             16 (1.5)                119 (3)                    0.004
  VT/VF requiring therapy                    74 (6.7)                148 (3.8)                  0.001
  AF requiring therapy                       48 (4.4)                263 (6.7)                  0.004
  Major bleeding                             2 (0.2)                 38 (1.0)                   0.009
  Blood transfusion                          28 (2.5)                226 (5.8)                  0.001
  Stroke                                     13 (1.2)                55 (1.4)                   0.56
  Systemic infection requiring antibiotics   229 (21)                979 (25)                   0.003
  Cardiac procedures                                                                            
  PCI                                        112 (10)                187 (5)                    0.001
  CABG                                       20 (2)                  49 (1.3)                   0.16
  Discharge medications                                                                         
  Digoxin                                    306 (28)                901 (23)                   0.001
  Oral nitrates                              405 (37)                1417 (36)                  0.81
  Hydralazine                                42 (4)                  311 (8)                    0.001
  Aspirin                                    925 (84)                2926 (75)                  0.001
  Clopidogrel                                522 (47)                1276 (33)                  0.001
  Oral anticoagulants                        157 (14)                740 (19)                   0.001
  Statin                                     775 (70)                2660 (68)                  0.19
  Ivabradine                                 66 (6)                  173 (4.4)                  0.03
  Antiarrhythmic                             57 (5)                  187 (5)                    0.61
   β Blockers                                798 (72)                2564 (66)                  0.001
  ACE inhibitors                             753 (68)                2129 (55)                  0.001
  ARBs                                       160 (15)                642 (17)                   0.12
  Aldosterone antagonists                    526 (48)                1530 (39)                  0.001
  Diuretics                                  975 (88)                3489 (89)                  0.32
  Length of stay, median (IQR), d            7 (4--10)               6 (4--11)                  0.16
  In‐hospital mortality                      53 (4.8)                260 (6.7)                  0.02

Data are given as number (percentage), unless otherwise indicated. Analyses were performed using Student *t* test, Wilcoxon‐Mann‐Whitney test, Pearson\'s χ^2^ test, or Fisher exact test, wherever appropriate. ACE indicates angiotensin‐converting enzyme; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; IABP, intra‐aortic balloon pump; IQR, interquartile range; NIV, noninvasive ventilation; PCI, percutaneous coronary intervention; VF, ventricular fibrillation; VT, ventricular tachycardia.
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Regression Models {#jah34420-sec-0018}
-----------------

The crude OR for in‐hospital mortality, according to smoking status (CS versus CN) at admission, was 0.71 (95% CI, 0.52--0.96; *P*=0.025). Multivariable logistic regression using covariate adjustment to determine the possibility of a causal effect of smoking on in‐hospital mortality revealed an even stronger protective effect for CS, with ≈50% reduction in odds of in‐hospital mortality (OR, 0.47; 95% CI, 0.31--0.70; *P*\<0.001), Using untrimmed PS values, the inverse probability of exposure‐weighted logistic regression with robust error variances resulted in a mortality OR of 0.63 (95% CI, 0.36--1.11; *P*=0.11). The trimmed data sets revealed a similar result after exclusion of 285 subjects (retained if PS values were between 0.01 and 0.99); the in‐hospital mortality OR for CS was 0.71 (95% CI, 0.41--1.24; *P*=0.233). After exclusion of 2057 subjects (retained if PS values were between 0.1 and 0.9), the in‐hospital mortality OR was 0.67 (95% CI, 0.45--1.00; *P*=0.049). Covariate balance was clearly achieved using the inverse probability weights, as depicted in the [Figure](#jah34420-fig-0001){ref-type="fig"} and Figures [S1](#jah34420-sup-0001){ref-type="supplementary-material"} and [S2](#jah34420-sup-0001){ref-type="supplementary-material"}.

![All subjects included. Covariate balance after using the inverse probability weights; horizontal lines denoting standardized differences of ±0.1; standardized differences that exceed thresholds are indicative of meaningful imbalance. Circles indicate standardized differences before propensity score (PS) adjustment, and squares indicate standardized differences after PS adjustment. acs Indicates precipitating acute coronary syndrome; admitHF, previous admission for heart failure; admitTO, where admitted in hospital; AFther, had atrial fibrillation requiring therapy; agecat, age category; aspirin, on aspirin before admission; AsthCOPD, history of asthma or chronic obstructive pulmonary disease; BMIgrp, body mass index category; CAD, coronary artery disease; ckddial, history of chronic kidney disease or dialysis; country, country of hospitalization; DM, diabetes mellitus; hilipid, history of hyperlipidemia; intvent, was intubated and/or on a ventilator; nyha, New York Heart Association class (heart failure); syncope, history of syncope in the past 1 year.](JAH3-8-e013056-g001){#jah34420-fig-0001}

Discussion {#jah34420-sec-0019}
==========

In the current study, we compared clinical presentation, risk factors, in‐hospital course, and mortality, stratified by smoking status, in a large group of patients hospitalized with acute HF. CS subjects were younger and had a lower risk profile compared with CN subjects. The in‐hospital mortality rates were also significantly lower in CS patients before and more so after covariate adjustment. After using the PS‐derived inverse probability of exposure weights, the smoking effect weakened and was no longer statistically significant. Given our results, we may be looking at reverse causality: healthier patients are more likely to continue to smoke. The smoking advantage demonstrated after covariate adjustment may be because the latter has been inadequate, as we have demonstrated herein and which has also been suggested by others.[22](#jah34420-bib-0022){ref-type="ref"} However, there have been studies suggesting attenuated endothelial dysfunction[23](#jah34420-bib-0023){ref-type="ref"} in CS subjects, although this may still reflect less severity of illness and, thus, reverse causality. Some researchers suggest that it is the smoking cessation enforced by hospitalization that improves outcome,[10](#jah34420-bib-0010){ref-type="ref"} although this is unlikely because of the result of this study.

From first mention of the smoker\'s paradox in 1995 and in the 15 years after this, there had been 7 randomized trials and 10 observational studies/registries published presenting the idea of the smoker\'s paradox in ACS[3](#jah34420-bib-0003){ref-type="ref"} but only one on HF per se.[2](#jah34420-bib-0002){ref-type="ref"} Since then, several studies using covariate adjustment have shown that CS status is protective. In one study, which defined CS to also include patients reported to have quit smoking during the past year, the in‐hospital mortality rate was lower in smokers, but smoking status was not an independent predictor of mortality.[24](#jah34420-bib-0024){ref-type="ref"} This paradoxical result can also be shown in young patients with acute MI in whom CS was an independent predictor of 8‐month cardiac death (OR, 0.25; 95% CI, 0.07--0.92; *P*=0.037) and total death (OR, 0.26; 95% CI, 0.09--0.82; *P*=0.021).[25](#jah34420-bib-0025){ref-type="ref"} The same has been found for the benefit resulting from routine early invasive management of unselected patients with acute non--ST‐segment--elevation MI, in whom the treatment effect of an early invasive strategy was more pronounced among CSs and not entirely explained by covariate adjustment.[26](#jah34420-bib-0026){ref-type="ref"} Finally, the only study in HF, to date, has demonstrated that someone who has smoked cigarettes any time during the year before hospital arrival (which was how CS was defined) had a better prognosis than CNs (labeled in their article as "nonsmokers").[2](#jah34420-bib-0002){ref-type="ref"}

PS analyses have also been previously done. One study that examined 29 199 patients with acute MI found that 42% were CS subjects, and the hazard ratio (HR) was 0.52 (95% CI, 0.47--0.58; *P*\<0.001), in favor of reduced mortality in the CS subjects at up to 1 year after acute MI. Covariate adjustment attenuated the effect, but the HR remained statistically significant (HR, 0.85; 95% CI, 0.76--0.95; *P*=0.005). However, the use of PS matching corroborated the results of reduced mortality among CSs (6.7% versus 7.6%; *P*=0.005).[27](#jah34420-bib-0027){ref-type="ref"} This suggests that PS matching may not be as effective as PS‐based weighting. Indeed, in other studies that have used PS‐based weights, the CS factor lost its influence in prognosis and the authors suggest that the smoking paradox is a finding that could be explained by other prognostic factors.[28](#jah34420-bib-0028){ref-type="ref"} This may also explain why CS seems to impart a covariate‐adjusted survival benefit in patients with other conditions, such as traumatic injuries.[5](#jah34420-bib-0005){ref-type="ref"}

In studies of smoking cessation on subjects with left ventricular dysfunction after MI using PS‐adjusted Cox proportional hazard models, the benefit of this cessation has been confirmed.[29](#jah34420-bib-0029){ref-type="ref"} In baseline smokers who survived to 6 months without interval events, smoking cessation at 6‐month follow‐up was associated with a significantly lower adjusted risk of all‐cause mortality (HR, 0.57; 95% CI, 0.31--0.91), death or recurrent MI (HR, 0.68; 95% CI, 0.47--0.99), and death or acute HF hospitalization (HR, 0.65; 95% CI, 0.46--0.92).[29](#jah34420-bib-0029){ref-type="ref"} These findings indicate that within a CS cohort, smoking cessation (beyond hospital admission) is beneficial after high‐risk MI, and this clearly indicates that smoking cannot be causally related to better prognosis if cessation itself leads to better prognosis. Other studies have shown that smoking is associated with lower 30‐day mortality (HR, 0.91; 95% CI, 0.87--0.94) but higher long‐term mortality (17‐year HR, 1.19; 95% CI, 1.17--1.20) after acute MI, in keeping with the hypothesis that continuing to smoke on admission is essentially a marker of a reduced severity of illness in terms of the underlying diagnosis.[30](#jah34420-bib-0030){ref-type="ref"} Overall, crude life expectancy estimates are also lower for smokers than nonsmokers at all ages, which translates into sizeable numbers of life‐years lost attributable to smoking.[30](#jah34420-bib-0030){ref-type="ref"} Given these and other similar findings,[31](#jah34420-bib-0031){ref-type="ref"} it is unlikely that the covariate‐adjusted estimates reported do imply causality. Finally, a recent study of HF has shown that if never smokers are the reference category, then there is a worse prognosis for CS.[32](#jah34420-bib-0032){ref-type="ref"} This suggests that smoking *per se* is harmful, but quitting because of illness on its own selects out those who have a worse prognosis. We could not test this hypothesis using our data as never smokers were not identified.

This study has a limitation of evaluating smoking history only at admission. In other words, people were classified as CSs or CNs. Thus, the burden of smoking was ignored and only behavior on admission was assessed. Therefore, the results in this article indicate the prognostic value of the smoking behavior at one time point (admission) and do not reflect the morbidity caused by smoking. This classification is in keeping with other epidemiological studies published previously.[33](#jah34420-bib-0033){ref-type="ref"} Another limitation is that with PS methods, there is the issue of extreme weights. It has been suggested that an analysis be done on a subsample with PS between 0.1 and 0.9. In the case of this study, this eliminates 41% of the sample and, thus, is ill advised. We suggest creating a subsample with PS between 0.01 and 0.99 as this limits the exclusions markedly. However, with either subsample, covariate balance was achieved, more so with PS values between 0.1 and 0.9.

We conclude that in studies of HF or of ACS, conditioning on the PS‐derived weight is better and obviates the need for adjustment. In addition, PS techniques allow one to measure marginal (or population‐average) treatment effects as opposed to covariate adjustment‐based approaches that allow one to estimate conditional (or adjusted) estimates of treatment effects. However, a recent evaluation of PS versus covariate adjustment in 4 large cardiovascular observational studies did not reveal a major difference between covariate adjustment and PS methods.[9](#jah34420-bib-0009){ref-type="ref"} This may be the case when confounding variables are not many, but if there are a multitude of confounders, then clearly PS methods are superior. The novel parts of this study include demonstration of this paradox in a Middle Eastern population and the documentation of residual confounding, even after accounting for known confounders in this understudied population. It is possible that such unknown confounders could be specific to this particular population and similarly hypothesized for other population studies. This paradox may be investigated further by collecting data on never smokers and using them as the reference for the analysis, but this needs to be tested in future studies or with existing data. Finally, we should point out that we examined potential confounding in this article as an explanation for the paradoxical results. Others[34](#jah34420-bib-0034){ref-type="ref"} have looked at the potential for paradoxical results caused by collider stratification bias (a form of selection bias). Obviously, if we balance/stratify/adjust on a collider, we introduce, rather than remove, bias, as indicated by Lajous et al[34](#jah34420-bib-0034){ref-type="ref"}; in their article, DM was a collider when the obesity‐mortality relationship was being examined and, thus, adjusting for or stratifying on DM induced bias, with strata based on DM having opposite associations. In the case of the "current smoking" behavior at admission and its association with mortality, all variables we adjust for or balance are confounders determined *a priori* by examining their putative association with exposure and outcome.

Conclusions {#jah34420-sec-0020}
===========

Our study shows that there is no survival advantage for CSs in patients hospitalized with HF. The current study underlines the need for future studies to also review the smoker\'s paradox phenomena reported in other chronic conditions with appropriate covariate balancing as this may demystify erroneous conclusions currently present in the medical literature. In addition, future studies should also focus on discovering the effect of unknown confounders using novel statistical methods, such as machine learning and use of electronic health records, which have a potential to improve our understanding of residual confounding in studies of chronic diseases.
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###### 

**Figure S1.** Limited to PS between 0.01 and 0.99. Covariate balance after using the inverse probability weights; horizontal lines denoting standardized differences of ±0.1, standardized differences that exceed thresholds indicative of meaningful imbalance. Circles indicate standardized differences prior to PS adjustment and squares indicate standardized differences after PS adjustment. acs indicates precipitating acute coronary syndrome; admitHF, previous admission for heart failure; admitTO, where admitted in hospital; AFther, had atrial fibrillation requiring therapy; agecat, age category; aspirin, on aspirin before admission; AsthCOPD, history of asthma or COPD; BMIgrp, BMI category; ckddial, history of CKD or dialysis; country, country of hospitalization; hilipid, history of hyperlipidemia; intvent, was intubated and/or on a ventilator; nyha, NYHA Class (heart failure); syncope, History of syncope in the last 1 year.

**Figure S2.** Limited to PS between 0.1 and 0.9. Covariate balance after using the inverse probability weights; horizontal lines denoting standardized differences of ±0.1, standardized differences that exceed thresholds indicative of meaningful imbalance. Circles indicate standardized differences prior to PS adjustment and squares indicate standardized differences after PS adjustment. acs indicates precipitating acute coronary syndrome; admitHF, previous admission for heart failure; admitTO, where admitted in hospital; AFther, had atrial fibrillation requiring therapy; aspirin, on aspirin before admission; AsthCOPD, history of asthma or COPD; BMIgrp, BMI category; ckddial, history of CKD or dialysis; country, country of hospitalization; gecat, age category; hilipid, history of hyperlipidemia; intvent, was intubated and/or on a ventilator; nyha, NYHA Class (heart failure); syncope, history of syncope in the last 1 year.
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Click here for additional data file.
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